Literature DB >> 32172145

Natural variability in seizure frequency: Implications for trials and placebo.

Juan Romero1, Phil Larimer1, Bernard Chang1, Shira R Goldenholz1, Daniel M Goldenholz2.   

Abstract

BACKGROUND: Changes in patient-reported seizure frequencies are the gold standard used to test efficacy of new treatments in randomized controlled trials (RCTs). Recent analyses of patient seizure diary data suggest that the placebo response may be attributable to natural fluctuations in seizure frequency, though the evidence is incomplete. Here we develop a data-driven statistical model and assess the impact of the model on interpretation of placebo response.
METHODS: A synthetic seizure diary generator matching statistical properties seen across multiple epilepsy diary datasets was constructed. The model was used to simulate the placebo arm of 5000 RCTs. A meta-analysis of 23 historical RCTs was compared to the simulations.
RESULTS: The placebo 50 %-responder rate (RR50) was 27.3 ± 3.6 % (simulated) and 21.1 ± 10.0 % (historical). The placebo median percent change (MPC) was 22.0 ± 6.0 % (simulated) and 16.7 ± 10.3 % (historical).
CONCLUSIONS: A statistical model of daily seizure count generation which incorporates quantities related to the natural fluctuations of seizure count data produces a placebo response comparable to those seen in historical RCTs. This model may be useful in better understanding the seizure count fluctuations seen in patients in other clinical settings.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical trials; Diary; Epidemiology; Seizures; Statistics

Year:  2020        PMID: 32172145      PMCID: PMC7194486          DOI: 10.1016/j.eplepsyres.2020.106306

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  56 in total

1.  Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials.

Authors:  Philippe Ryvlin; Michel Cucherat; Sylvain Rheims
Journal:  Lancet Neurol       Date:  2011-09-19       Impact factor: 44.182

2.  Clinical relevance of patients with epilepsy included in clinical trials.

Authors:  Eva Tlusta; Kim B Handoko; Marian Majoie; Toine C G Egberts; Jiri Vlcek; Eibert R Heerdink
Journal:  Epilepsia       Date:  2008-08       Impact factor: 5.864

3.  The impact of missing data in a generalized integer-valued autoregression model for count data.

Authors:  Mohamed Alosh
Journal:  J Biopharm Stat       Date:  2009-11       Impact factor: 1.051

Review 4.  Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.

Authors:  Sylvain Rheims; Emilio Perucca; Michel Cucherat; Philippe Ryvlin
Journal:  Epilepsia       Date:  2011-01-26       Impact factor: 5.864

Review 5.  Placebo and nocebo responses in drug trials of epilepsy.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Dieter Schmidt
Journal:  Epilepsy Behav       Date:  2015-02-19       Impact factor: 2.937

6.  Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study.

Authors:  Victor Biton; Juan Di Memmo; Rakesh Shukla; Yeong Yeh Lee; Irina Poverennova; Vladislav Demchenko; Jane Saiers; Bryan Adams; Anne Hammer; Alain Vuong; John Messenheimer
Journal:  Epilepsy Behav       Date:  2010-10-30       Impact factor: 2.937

7.  A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures.

Authors:  Michel Baulac; Teresa Leon; Terence J O'Brien; Edward Whalen; Jeannette Barrett
Journal:  Epilepsy Res       Date:  2010-08-08       Impact factor: 3.045

8.  Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial.

Authors:  Péter Halász; Reetta Kälviäinen; Maria Mazurkiewicz-Beldzińska; Felix Rosenow; Pamela Doty; David Hebert; Timothy Sullivan
Journal:  Epilepsia       Date:  2009-01-17       Impact factor: 5.864

9.  Seizure frequency in intractable partial epilepsy: a statistical analysis.

Authors:  M Balish; P S Albert; W H Theodore
Journal:  Epilepsia       Date:  1991 Sep-Oct       Impact factor: 5.864

10.  Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.

Authors:  Santiago Arroyo; Henning Anhut; Alan R Kugler; Caroline M Lee; Lloyd E Knapp; Elizabeth A Garofalo; Silke Messmer
Journal:  Epilepsia       Date:  2004-01       Impact factor: 5.864

View more
  3 in total

1.  Seizure Cycles in Focal Epilepsy.

Authors:  Marc G Leguia; Ralph G Andrzejak; Christian Rummel; Joline M Fan; Emily A Mirro; Thomas K Tcheng; Vikram R Rao; Maxime O Baud
Journal:  JAMA Neurol       Date:  2021-04-01       Impact factor: 18.302

2.  Can machine learning improve randomized clinical trial analysis?

Authors:  Juan Romero; Sharon Chiang; Daniel M Goldenholz
Journal:  Seizure       Date:  2021-08-02       Impact factor: 3.414

3.  Guidelines for Conducting Ethical Artificial Intelligence Research in Neurology: A Systematic Approach for Clinicians and Researchers.

Authors:  Sharon Chiang; Rosalind W Picard; Winston Chiong; Robert Moss; Gregory A Worrell; Vikram R Rao; Daniel M Goldenholz
Journal:  Neurology       Date:  2021-07-27       Impact factor: 11.800

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.